Detalles de la búsqueda
1.
Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.
Antimicrob Agents Chemother
; 65(12): e0138121, 2021 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34543098
2.
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
Antimicrob Agents Chemother
; 65(11): e0036421, 2021 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34460307
3.
Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact.
J Antimicrob Chemother
; 75(5): 1123-1129, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32016320
4.
Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.
Antimicrob Agents Chemother
; 63(3)2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30617089
5.
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.
Am J Respir Crit Care Med
; 198(9): 1208-1219, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29877726
6.
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
J Antimicrob Chemother
; 73(10): 2667-2674, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29982641
7.
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Antimicrob Agents Chemother
; 59(1): 38-45, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25313213
8.
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.
Lancet
; 383(9924): 1230-9, 2014 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24439237
9.
Minority Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance.
Am J Respir Cell Mol Biol
; 61(6): 789-791, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31774334
10.
Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.
Antimicrob Agents Chemother
; 58(5): 2912-5, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24514091
11.
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
Antimicrob Agents Chemother
; 58(1): 503-10, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24189253
12.
The pyrazinamide susceptibility breakpoint above which combination therapy fails.
J Antimicrob Chemother
; 69(9): 2420-5, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24821594
13.
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
J Antimicrob Chemother
; 67(5): 1088-93, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22357804
14.
embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis.
Chemotherapy
; 58(5): 358-63, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23171739
15.
Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.
J Med Chem
; 64(1): 719-740, 2021 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33395287
16.
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis.
J Med Chem
; 64(17): 12790-12807, 2021 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34414766
17.
Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.
Lancet Respir Med
; 5(4): 269-281, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28109869
18.
Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.
J Med Chem
; 60(24): 10118-10134, 2017 12 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29148755
19.
Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.
Emerg Microbes Infect
; 4(7): e42, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26251830
20.
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.
PLoS One
; 8(3): e59414, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23527189